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Objective: Interleukin-1 is one of the inﬂammatory cytokines elevated after traumatic joint injury that
plays a critical role in mediating cartilage tissue degradation, suppressing matrix biosynthesis, and
inducing chondrocyte apoptosis, events associated with progression to post-traumatic osteoarthritis
(PTOA). We studied the combined use of insulin-like growth factor-1 (IGF-1) and dexamethasone (Dex)
to block these multiple degradative effects of cytokine challenge to articular cartilage.
Methods: Young bovine and adult human articular cartilage explants were treated with IL-1a in the
presence or absence of IGF-1, Dex, or their combination. Loss of sulfated glycosaminoglycans (sGAG) and
collagen were evaluated by the DMMB and hydroxyproline assays, respectively. Matrix biosynthesis was
measured via radiolabel incorporation, chondrocyte gene expression by qRT-PCR, and cell viability by
ﬂuorescence staining.
Results: In young bovine cartilage, the combination of IGF-1 and Dex signiﬁcantly inhibited the loss of
sGAG and collagen, rescued the suppression of matrix biosynthesis, and inhibited the loss of chondrocyte
viability caused by IL-1a treatment. In adult human cartilage, only IGF-1 rescued matrix biosynthesis and
only Dex inhibited sGAG loss and improved cell viability. Thus, the combination of IGF-1 þ Dex together
showed combined beneﬁcial effects in human cartilage.
Conclusions: Our ﬁndings suggest that the combination of IGF-1 and Dex has greater beneﬁcial effects
than either molecule alone in preventing cytokine-mediated cartilage degradation in adult human and
young bovine cartilage. Our results support the use of such a combined approach as a potential treatment
relevant to early cartilage degradative changes associated with joint injury.
© 2014 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Post-traumatic osteoarthritis (PTOA) refers to the development
of OA as a result of traumatic joint injury. PTOA accounts for 12% of
the OA population and typically affects younger individuals1,2. The
pathogenesis followingacute joint injuries (such as anterior cruciate
ligament rupture and/ormeniscal tear) has been reported to involve
an immediate increase in synovial ﬂuid concentrations of pro-
inﬂammatory cytokines (e.g., IL-13e5, TNF-a3e7, and IL-63e7), alongto: A. J. Grodzinsky, MIT
-4969; Fax: 1-617-258-5239.
ternational. Published by Elsevier Lwith increased release of cartilage matrix fragments and noticeable
chondrocyte apoptosis8,9. While cytokine levels eventually drop to
that found in chronic OA3, their continued presence upsets the
balance between anabolic and catabolic processes in cartilage,
which plays an important role in the progression to PTOA10.
An ideal pharmacological intervention to prevent or delay the
onset of PTOA should address several if not all of the pathogenic
responses to joint injury; such intervention should inhibit inﬂam-
matory responses, prevent cell death, prevent cartilage matrix
degradation, and promote production of new matrix11. Recent
studies have explored the potential of several therapeutic ap-
proaches: IL-1 receptor antagonists (IL-1Ra) and TNF-a blockers to
inhibit selected inﬂammatory mediators10,12, metalloproteinase
and aggrecanase inhibitors to reduce matrix degradation10, andtd. All rights reserved.
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matrix production and cell proliferation and counteract matrix
degradation13. However, these studies all focused on targeting a
single, speciﬁc pathway/molecule; many investigators now believe
that no single compound will be sufﬁcient to treat every aspect of
OA14, and that a combination of therapeutics will be necessary to
address multiple pathogenic mechanisms.
In the current study, we take a novel approach by systematically
studying the potential of a combination therapeutic to achieve both
pro-anabolic and anti-catabolic effects, and at the same time, to
improve cell viability. Insulin-like growth factor-1 (IGF-1) is a potent
growth factor that can upregulate cartilagematrix biosynthesis and,
under certain circumstances, inhibit catabolic processes stimulated
by cytokines15,16. IGF-1 binds to the chondrocyte IGF-1 receptor and
transduces signals via the IRS-1/PI3K/Akt pathway, which regulates
protein synthesis17. In addition, IGF-1 provides pro-survival signals
and has been shown in vitro to rescue chondrocyte apoptosis
induced by collagen degradation18 and by mechanical injury19.
Dexamethasone (Dex), a potent synthetic glucocorticoid (GC), has
been widely used intra-articularly to relieve inﬂammation for the
treatment of OA and other arthritis20. Dex has been shown to block
cytokine-induced cartilage matrix catabolism and to alleviate
cytokine-induced inhibition of matrix biosynthesis in bovine carti-
lage via GC receptor-dependent pathways21. The ability of this
combination of IGF-1 and Dex to modulate cytokine-mediated
cartilage degradation and to simultaneously maintain chondrocyte
viability in the face of cytokine challenge remains to be elucidated.
Using adult human knee and ankle cartilage and young bovine
cartilage in an in vitro model system, our objectives were to
quantify the effects of IGF-1, Dex and their combination on IL-1-
induced degradation of aggrecan and collagen, inhibition of pro-
teoglycan biosynthesis, and altered chondrocyte viability. Further-
more, we examined the hypothesis that the effects of IGF-1 and Dex
are consequences of their direct transcriptional regulation by
comparing changes at the protein level to their effects at the level of
gene transcription.
Materials and methods
Bovine cartilage harvest and culture
Cartilage disks were harvested from the femoropatellar grooves
of 1e2-week-old calves (obtained from Research 87, Boylston, MA).
Explants were harvestedwithin 8 h after animal death and a total of
15 joints from 14 animals were used. Brieﬂy, a 3-mm dermal punch
was used to core full-thickness cartilage cylinders, and the top 1-
mm disk containing intact superﬁcial zone was obtained with a
blade. For each experiment, disks from different treatment groups
werematched for anatomic location along the joint surface. Explant
disks were then equilibrated in serum-free medium: low glucose
Dulbecco'sModiﬁed EagleMedium (DMEM); 1 g/L (Corning Cellgro,
Manassas, VA) supplemented with 10 mM HEPES buffer (Gibco,
Grand Island, NY), 0.1 mMnonessential amino acids (Sigma Aldrich,
St. Louis, MO), 0.4 mM proline (Sigma), 20 mg/ml ascorbic acid
(Sigma), 100 units/ml penicillin G, 100 mg/ml streptomycin, and
0.25 mg/ml amphotericin B (Sigma) for 2e3 days (5% CO2; 37C).
Serum-free conditions were chosen to distinguish the speciﬁc ef-
fects of exogenous IGF-1 from the unknown concentrations of
endogenous growth factors that may be present in serum.
Adult human cartilage harvest and culture
Cartilage from adult human knee and ankle joints was obtained
postmortem from the Gift of Hope Organ and Tissue Donor Network
(Itasca, IL). All procedures were approved by the Rush UniversityMedical Center Institutional Review Board (ORA Number:
08082803-IRB01-AM01) and the Committee on the Use of Humans
as Experimental Subjects atMIT. At the time of donor tissue harvest,
the joint surfaces were scored by an experienced forensic patholo-
gist using the modiﬁed Collins grading system22. 20 joints from 13
donors were used in this study (an ankle/knee pair was obtained
from one donor, and ankle pairs were obtained from six donors). 14
ankle joints (Collin's grade 1) were from eight donors, age 64e76
years old (see Supplementary Table S1 for enumeration of joints).
Six knee joints (Collin's grade 0e2)were from six donors, age 19e66
years old. Full-thickness (~1e2 mm) cartilage disks cored with a 3-
mm punch were harvested from the talar domes of ankles and the
tibial plateau or distal femur of knees. Explants were harvested
within 24e36h afterdeath of donors andonlyunﬁbrillated cartilage
was used. Joint surfaces excluded from the study were the visibly
roughened surfaces where the superﬁcial layer had clearly lost its
smooth architecture and the collagen appeared to be ﬁbrillated. In
order to be consistent with a previous study using human tissue23,
human explants were equilibrated for 2e3 days in high glucose
DMEM (4.5 g/L; Corning Cellgro, Manassas, VA) containing the same
supplements as in the bovine culture medium. To determine the
effects of glucose concentration on cartilage response, a separate
control study was performed using explants from three additional
knee joints and six additional ankle joints (Table S1, Fig. S5) cultured
in low glucose DMEM with otherwise identical supplements.
Dose responses of IGF-1 and Dex in the presence of IL-1
Many studies of cartilage explants treated with IL-1 have been
reported utilizing IL-1 concentrations ranging from 0.05 to 100 ng/
ml15,24. Based on our own preliminary doseeresponse study of
sGAG loss vs IL-1a (R&D Systems, Minneapolis, MN) at 1, 2, 5, and
10 ng/ml) with bovine cartilage, we chose an IL-1a concentration of
1 ng/ml for all the present experiments, representing a moderately
aggressive cytokine treatment. We then tested the effects of Dex
(Sigma) alone (at 10 nM, 100 nM and 1 mM) and IGF-1 (R&D Sys-
tems) alone (at 10, 100 and 300 ng/ml) on sGAG loss and proteo-
glycan biosynthesis in bovine cartilage treated with 1 ng/ml IL-1a.
Based on the results of these dose response studies [Fig. 1(A and B)],
we chose concentrations of 100 nM Dex and 100 ng/ml IGF-1, both
alone and in combination, for all subsequent tests of sGAG loss,
biosynthesis, gene expression and cell viability.
Biosynthesis, sGAG, and biochemical analysis
Cartilage disks were radiolabeled with 5 mCi/ml 35S-sulfate
(Perkin-Elmer, Norwalk, CT) for 36e48 h. When terminated, disks
were washed in PBS, weighed and digested with proteinase K
(Roche, Indianapolis, MN). Radiolabel incorporation was measured
using a liquid scintillation counter (PerkinElmer), and normalized
to DNA for bovine explants (measured via Hoechst 33258 dye-
binding assay25), and to wet weight for human explants. The
DMMB dye-binding assay26 and hydroxyproline assay27 was used
to determine the sGAG content and collagen content, respectively,
of digested cartilage explants and medium. The sGAG and collagen
content data were expressed as a percentage of the total sGAG or
collagen, respectively.
Cell viability
Slices (100e200 mm thick) were cut with a scalpel from the
center of cartilage disks28 (see Supplementary Figure S1 for slice
orientation) and incubated for 2e3 min in the dark in PBS con-
taining ﬂuorescein diacetate (FDA; 4 mg/ml) and propidium iodide
(PI; 40 mg/ml) (both from Sigma), for viable and non-viable cell
Fig. 1. A, Percent sGAG loss from immature bovine cartilage in an 8-day dose response experiment. Disks were subjected to different doses of Dex or IGF-1 in the presence of IL-1a
(1 ng/ml); 23e24 disks/condition from n ¼ 4 animals. B, Normalized sulfate incorporation rate measured during Day 6e8 of the same disks in A. C, Percent sGAG loss in response to
8-day treatments using 18 disks/condition from n ¼ 3 animals. D, Normalized sulfate incorporation rate measured during Day 6e8 of the same disks used in C. Values are mean and
95% conﬁdence interval, * vs untreated control (P < 0.0001); # vs IL-1a alone (P < 0.0001); $: P < 0.0001.
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1 mm  3 mm area of each slice from superﬁcial surface to 1 mm
deep was imaged using a Nikon ﬂuorescence microscope at 4
magniﬁcation. 1e2 slices were imaged (2 images/slice) for each
sample. For human cartilage disks, cell viability was quantiﬁed
using ImageJ. The numbers of viable and non-viable cells were
counted over each entire slice via the Image-based tool for
Counting Nuclei (ITCN version 1.6) plug-in, and data were
expressed as percent of total viable cells.
Gene expression analyses
Bovine cartilage disks from ﬁve animals (six disks per condition
per animal) were treated for 4 days and stored in80C after ﬂash-
freezing. Using methods described in detail previously29,30, the six
disks from each condition were pooled, pulverized, and homoge-
nized in TRIzol reagent, and then separated using phase-gel tubes
(Eppendorf, Hamburg, Germany). The supernatant was puriﬁed
following the Qiagen RNeasymini kit protocol (Qiagen, Chatsworth,
CA). Equal amounts of mRNA from each condition were reverse
transcribed using the AmpliTaq-Gold Reverse Transcription kit
(Applied Biosystems, Foster City, CA). Primer pairs used were pre-
viously reported29,30 except for caspase-3: forward 50-GAAGTCT-
GACTGGAAAACCC-30, reverse 50- GAAGTCTGCCTCAACTGGTA-30.
Real-time PCR were performed using the Applied Biosystems
7700HT instrument with SYBR Green Master Mix (Applied Bio-
systems). Expression data for each gene were calculated from the
threshold cycle (Ct) value, and normalized to the internal house-
keeping gene 18S. Our previous studies explored several house-
keeping genes and normalization methods and, in the system used
here, in the absence of impact mechanical injury to cartilage,
normalization to 18s and G3PDH gave similar results29,30.
Statistical analysis
Bovine and human sGAG loss and biosynthesis data, bovine
collagen loss data, bovine gene expression data, and humanviability data were analyzed using the linear mixed effects model
with animal (or human donor) as a random factor, followed by
Tukey's Honestly Signiﬁcant Difference (Tukey's HSD) test for pair-
wise comparisons. Statistical tests were performed using either
Systat 12 or JMP Pro 11 software. P-values less than 0.05 were
considered statistically signiﬁcant.
Results
Combined Dex plus IGF-1 treatment is most effective in ameliorating
IL-1a-induced GAG loss and inhibition of biosynthesis in bovine
cartilage
The effects of IGF-1, Dex, and the combination of IGF-1 and Dex
on IL-1a-treated bovine cartilage were examined in three inde-
pendent 8-day experiments (three animals). Consistent with pre-
vious reports, IGF-1 alone and Dex alone were each able to reduce
the loss of sGAG caused by IL-1a treatment [Fig. 1(C)]. Similarly,
IGF-1 alone and Dex alone partly reversed the inhibition of pro-
teoglycan biosynthesis caused by IL-1a [Fig. 1(D)], though Dex was
less effective than IGF-1. However, the combination of IGF-1 þ Dex
showed signiﬁcant further reduction in sGAG loss and higher
biosynthesis compared to either Dex or IGF-1 alone. The concen-
tration of Dex and IGF-1 used for the combination study was based
on these dose response experiments [Fig. 1(A and B), and
Supplementary Fig. S2 which shows separately the sGAG content
remaining in explants and that lost to the medium by Day 8 cor-
responding to the experiments of Fig. 1(A)].
The combined effects of IGF-1 and Dex on collagen degradation
Bovine explants were cultured in IL-1a medium for 25 days to
study the kinetics of sGAG and collagen release to the medium.
During the ﬁrst 10 days, IL-1a induced signiﬁcantly more sGAG loss
compared to untreated controls, consistent with the previously
reported activity of ADAMTS-431 [Fig. 2(A), P < 0.0001], while
collagen release was negligible from both control and IL-1a-treated
cartilage. By Day 12, when ~85% sGAG was depleted from IL-1a-
Fig. 2. A, Kinetics of sGAG and collagen (OH-proline) loss from immature bovine cartilage disks in response to 25-day treatment with 1 ng/ml IL-1a; N ¼ 6 disks. B, Accumulated
collagen loss to the medium from Day 12e24 for cartilage disks in response to 24-day treatments. IL-1a (1 ng/ml) was added on Day 0 while IGF-1 (100 ng/ml) and Dex (100 nM)
were introduced on Day 12 after the majority of sGAG was depleted; 18e20 disks/condition from n ¼ 3 independent experiments. Values are mean and 95% conﬁdence interval, * vs
IL-1a alone; # vs IL-1a þ IGF-1; $ vs IL-1a þ Dex, P < 0.05.
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vs 1.1%, P¼ 0.0378). By Day 25, collagen loss reached 68.8% for IL-1a
treatment vs 2.1% for controls [Fig. 2(A); P < 0.0001].
Next, we examined the effects of IGF-1 and Dex on the extent of
IL-1a-induced collagen release that would occur after substantial
sGAG had already been lost, as a model for treatment during the
earliest stages of PTOA-like inﬂammatory challenge (three inde-
pendent experiments with three animals). IL-1a treatment was
maintained over the entire 24-day study, but IGF-1, Dex, or the
combination was not introduced until Day 12, by which time ~70%
GAG release had already occurred. (Total sGAG content remaining
in the explants after 24 days of culture and that lost to the medium
from day 0e24 are shown separately in Supplementary Fig. S3.)
During days 12e24, IL-1a alone caused cumulative collagen
release of 58% vs 1.1% in the untreated controls [Fig. 2(B);
P < 0.0001]. This collagen release was markedly attenuated by IGF-
1 alone to 23.8% (P < 0.0001) and by Dex alone to 14.2% (P ¼ 0.008
vs IL-1a þ IGF-1). Combination treatment with IGF-1 and Dex
reduced collagen loss to only 7.9% (P ¼ 0.028 vs IL-1a þ Dex).Fig. 3. A, Bovine chondrocyte viability in cartilage disks in response to 8, 16, or 24-day treat
were ﬂuorescently labeled with ﬂuorescein diacetate (green, viable) and propidium iodide (
Disks were treated with IL-1a (1 ng/ml) for the ﬁrst 8 days, and switched to 1 pg/ml IL-1a bet
Day 8 (middle panel) or Day 0 (bottom panel). White arrow: intact superﬁcial surface of caCollagen release kinetics revealed that the effects of IGF-1
(P ¼ 0.0113) or Dex (P < 0.0001) alone, became signiﬁcantly
different from IL-1a by Day 18 [Fig. 2(B)], while combined [IGF-
1 þ Dex] (P ¼ 0.001) treatment became signiﬁcant by Day 15.
Furthermore, the combination treatment completely arrested
collagen release between Days 15e24 [Fig. 2(B)]. (Total hydroxy-
proline content remaining in explants after 24 days of culture and
that lost to the medium from days 12e24 are shown in
Supplementary Fig. S4.)
IGF-1 and Dex maintained bovine chondrocyte viability in the
presence of IL-1a
Bovine disks were cultured in IL-1a medium with or without
Dex for 8, 16, and 24 days [Fig. 3(A)]. Increased cell death was
observed as early as 8 days after IL-1a treatment, and by Day 24,
disks had undergone severe degeneration [Fig. 3(A), bottom-
middle column]. In contrast, addition of Dex greatly reduced IL-
1a-induced cell death and its effects were sustained over 24 days. In
separate experiments [Fig. 3(B)], IGF-1, Dex, or both greatly reducedments. Treatment groups are control, IL-1a (1 ng/mL), and IL-1a þ Dex (100 nM). Cells
red, non-viable). B, Bovine chondrocyte viability evaluated on Day 16 after treatments.
ween Day 8 and Day 16. IGF-1 (100 ng/ml), Dex (100 nM), or both were added either on
rtilage. Scale bar ¼ 200 mm.
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rescuing effects were not observed when added on Day 8.
Bovine chondrocyte gene expression
mRNA levels of aggrecan and collagen II were signiﬁcantly
downregulated by IL-1a after 4-day treatment (Fig. 4). The addition
of Dex or the combination reversed downregulation of aggrecan
expression compared to IL-1a alone; the effect of Dex was greater
than that of IGF-1. In contrast, only the combination treatment
reversed inhibition of collagen II expression (Fig. 4). ADAMTS-4
expression was upregulated by IL-1a, but was suppressed by IGF-
1, Dex, or the combination. IL-1a increased ADAMTS-5 expression
by greater than 200-fold, which was reversed by IGF-1 or Dex
alone; the combination showed a further reduction compared to
either treatment alone. IL-1a also elevated mRNA levels of the
proprotein convertases PACE-4 and Furin, which in turn were
signiﬁcantly suppressed by the combination of IGF-1 and Dex
(Fig. 4). MMP-3 and MMP-13 were similarly upregulated several
hundred fold by IL-1a; adding IGF-1 had no effect on either gene
(P ¼ 0.103 for MMP-3; P ¼ 0.057 for MMP-13), whereas Dex or the
combination markedly reduced both genes (Fig. 4). mRNA levels of
COX-2 were upregulated by IL-1a, but suppressed by IGF-1, and
further reduced by Dex (Fig. 4). IL-1a signiﬁcantly increased iNOS
expression, but IGF-1, Dex, or their combination had no additional
effect. Dex completely blocked IL-1a-induced increases in IL-6
expression, while IGF-1 showed no effect at all. The apoptosis
executioner gene caspase-3 was increased by IL-1a treatment, but
was signiﬁcantly reduced by Dex or Dexþ IGF-1; however, IGF-1 by
itself had no suppressive effect (Fig. 4).Fig. 4. The effects of IGF-1 (100 ng/ml) and Dex (100 nM) on bovine chondrocyte gene expre
from the same animal were pooled for mRNA extraction; n ¼ 5 animals. Gene expression
control condition which had an expression level ¼ 1 (dotted line). Data are presented as
(P < 0.001); $:P < 0.001.Only Dex suppressed IL-1-induced GAG loss in human cartilage
sGAG loss from human ankle and knee cartilage induced by IL-
1a was evaluated in a 17-day study (eight independent experi-
ments, ﬁve for ankle and three for knee). IL-1a signiﬁcantly
increased sGAG loss compared to untreated controls [Fig. 5(A and
C); P < 0.0001 for both ankle and knee cartilage]. Dex completely
blocked sGAG loss compared to IL-1a alone (P < 0.0001, both ankle
and knee) to a level not different from the untreated controls
(P¼ 0.0762 for ankle; P¼ 0.5418 for knee). However, the addition of
IGF-1 did not reduce elevated sGAG release. The combination of
Dex and IGF-1 showed similar results as Dex alone. As these human
explant cultures were maintained in high glucose DMEM and the
bovine cultures above were in low glucose DMEM, we conducted
additional experiments with six ankle joints (three donors) and
three knee joints (three donors, Table S1) to test whether glucose
concentration altered the catabolic response of these human tis-
sues. We found that glucose concentration does not change our
conclusion regarding the ability of Dex to suppress sGAG loss in
adult human donor tissues under cytokine challenge, whether by
IL-1 or [TNFa þ IL-6/sIL-6R] (Supplementary Fig. S5).
Only IGF-1 could rescue chondrocyte biosynthesis in human
cartilage
In the same 17-day study with human cartilage explants (Fig. 5),
35S-sulfate incorporation rates as a measure of proteoglycan
biosynthesis were measured during Day 15e17. Compared to un-
treated controls, biosynthesis was suppressed by IL-1a treatment inssion after 4-day treatment with IL-1a (1 ng/ml). For each condition, six cartilage disks
levels were normalized to that of the 18S gene and then normalized to the untreated
mean ± 95% conﬁdence interval, * vs untreated control (P < 0.001); # vs IL-1a alone
Fig. 5. A, Percent sGAG loss from adult human ankle cartilage in response to 17-day treatments, N ¼ 40 disks from n ¼ 5 donors (one independent experiment per donor). B,
Normalized sulfate incorporation rate during Day 15e17 for the same cartilage disks used in A above. C, Percent sGAG loss from adult human knee cartilage in response to 17-day
treatments, N ¼ 24 disks from n ¼ 3 donors (1 independent experiment per donor). D, Normalized sulfate incorporation rate during Day 15e17 of the same disks in C, Values are
mean and 95% conﬁdence interval. * vs untreated control (P < 0.0001); # vs IL-1a alone (P < 0.0001); $: P < 0.0001.
Y. Li et al. / Osteoarthritis and Cartilage 23 (2015) 266e274 271both ankle and knee cartilage [Fig. 5(B and D); P < 0.0001 for both].
IGF-1 reversed this inhibition of biosynthesis in the ankle
(P < 0.0001) and knee (P ¼ 0.0196), whereas Dex had no effect
(P ¼ 0.3452 in ankle, P ¼ 0.979 in knee). The combination of IGF-1
and Dex signiﬁcantly increased biosynthesis but the effect was
similar to IGF-1 alone (P¼ 0.3936) in the ankle. IGF-1þ Dex did not
reverse the effects of IL-1a treatment in knee cartilage (P¼ 0.3194),
but was similar to the effect of IGF-1 alone (P ¼ 0.7764).Fig. 6. A, Representative images of ﬂuorescently stained adult human ankle cartilage on Da
propidium iodide (red, non-viable). White arrow: superﬁcial surface. Scale bar ¼ 200 mm. B,
human knee cartilage (64-yr-old female ankle, N ¼ 6 disks; 66-yr-old female ankle, N ¼ 4
conﬁdence interval, * vs untreated control; $ vs IL-1a þ Dex, P value <0.0001. C, Depth-de
divided into ﬁve zones, with 0e10% as the superﬁcial zone. The deepest 5% depth was notOnly Dex maintained human chondrocyte viability in the presence
of IL-1a
Chondrocyte viability in human cartilage explantswas evaluated
17 days after treatment on two ankle joints and a knee joint.
Representative images indicated signiﬁcant cell death occurred
under IL-1a treatment [Fig. 6(A)], especially in the superﬁcial zone,
and only Dex treatment rescued cell death. Quantitative resultsy 17 after treatments. Cells were labeled with ﬂuorescein diacetate (green, viable) and
Quantiﬁed percent viability from red/green images of two adult human ankles and one
disks; same 66-yr-old female knee, N ¼ 12 disks). Data are presented as mean ± 95%
pendent cell viability in the 64-yr-old female ankle cartilage. Each slice of a disk was
included in the analysis due to cutting-induced cell death.
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speciﬁcally, IL-1a induced signiﬁcant cell death compared to the
untreated controls [Fig. 6(B)]. Addition of IGF-1 showed no rescue of
cell viability while addition of Dex rescued overall viability of
chondrocytes in the presence of IL-1a. The combination of IGF-1 and
Dex showed no signiﬁcant difference compared to IGF-1 alone
(P ¼ 0.6789) in rescuing cell viability. A majority of IL-1a-induced
cell death occurred in the superﬁcial and middle zones of ankle
cartilage [Fig. 6(C)], and only the addition of Dex rescued cell death
throughout the entire depth of the cartilage disks.
Discussion
We tested the hypothesis that the combination of potent anti-
catabolic and pro-anabolic agents could ameliorate degradative
effects of inﬂammatory cytokines known to be upregulated during
the earliest stages following acute joint injury. Using IL-1a as a
model of cytokine challenge in vitro, our results demonstrated that
IGF-1 and Dex complemented each other in adult human cartilage;
speciﬁcally, IGF-1 promoted matrix biosynthesis while Dex blocked
matrix loss and preserved cell viability. Importantly, these beneﬁ-
cial effects could not be achieved by either agent alone. In young
bovine cartilage, both IGF-1 and Dex provided pro-anabolic and
anti-catabolic effects, and these combined effects were additive or
synergistic. While Dex preserved cell viability during IL-1a chal-
lenge in both adult human and young bovine cartilage, IGF-1 only
offered protection in young bovine cartilage. Lastly, we hypothesize
that the observed changes at the protein level are consistent with
the observed transcriptional upregulation by IGF-1 and Dex of
aggrecan and collagen II gene expression, and suppression on
MMPs, aggrecanases ADAMTS-4 and -5 mRNA, as well as propro-
tein convertases Furin and PACE 4.
We found for the ﬁrst time that for the case of human articular
cartilage, Dex was more effective in maintaining chondrocyte
viability and minimizing GAG loss, while IGF-1 was more effective
at reversing the effects of cytokine-induced inhibition of GAG
synthesis; thus, the use of a combined therapeutic approach was
better than either individual treatment alone. The combined ability
of Dex and IGF-1 treatment to protect against collagen degradation
even after substantial aggrecan GAG loss has already occurred
[Fig. 2(B)] is demonstrated clearly using bovine articular cartilage.
Together, these results suggest that it may be possible to preserve
the matrix ﬁbrillar structure and enable time for replenishment of
aggrecan (and other matrix constituents) given suitable pro-
anabolic stimulation of biosynthesis by viable chondrocytes,
wherein cell viability and broad spectrum inhibition of cytokine-
induced degradation can be maintained by simultaneously deliv-
ered factors.
Certain mechanisms by which [IGF-1 þ Dex] can prevent pro-
teoglycan degradation in the presence of IL-1a appear to manifest
at the level of gene transcription. In addition to inhibition of
aggrecanase transcription (Fig. 4), IGF-1 has been reported to
reduce the abundance of MMP-13 protein secreted by chondrocytes
and to decrease mRNA levels of certain MMPs32, though the
decrease in MMP-13 expression in Fig. 4 was not signiﬁcant. Here,
we have added new information by showing that IGF-1 can sup-
press collagen loss even after themajority of sGAG is depleted by IL-
1a [Fig. 2(B)]. We found that Dex may further protect collagen by
suppressing MMP-13 expression (Fig. 4), consistent with previous
studies33,34. Thus, the combination of Dex and IGF-1 provides
marked protection of collagen that cannot be achieved by either
agent alone.
The strong increase in IL-6 mRNA levels by IL-1a suggests that
the effects of IL-1a may be augmented by IL-6. Interestingly, Dex
strongly suppressed IL-6 gene expression (Fig. 4). Guerne et al.35showed that Dex (100 nM) rescued the inhibition of PG synthesis
caused by IL-6/sIL-6 or IL-6 observed in primary human chon-
drocyte culture. Dex likely counteracts the suppressive effects of
inﬂammatory cytokines on matrix biosynthesis rather than directly
promoting biosynthesis.
A surprising ﬁnding of this study is that Dex prevented IL-1a-
induced chondrocyte cell death in both young bovine and adult
human cartilage. We know of no previous report describing the
effects of Dex on cytokine-induced chondrocyte cell death in hu-
man cartilage explants. In the literature, the effects of Dex on
chondrocyte death have been contradictory. Comparison between
studies is difﬁcult because of the widely varying Dex dosages used,
differences in cell types, culture conditions, the use of isolated cells
vs explants in vitro, differences in animal species in vivo, and dif-
ferences in outcomes measures used. For example, Dex induced
apoptosis in proliferative chondrocytes cell lines36,37, isolated pri-
mary chondrocytes38, and in terminally differentiated hypertrophic
chondrocytes39. In contrast, Dex prevented apoptosis in terminally
differentiated murine cell lines40 and did not compromise cell
viability in long-term culture of bovine cartilage explants41. These
ﬁndings suggest that the pro- or anti-apoptotic nature of Dex is cell
type-, cell differentiation stage-, dose-, as well as stimulus-
dependent. Therefore, when cartilage is challenged with IL-1a,
we speculate that Dex interferes with cytokine-induced apoptotic
signaling network. This is supported by the downregulation of
caspase-3 mRNA expression by Dex in the present study. The
mechanistic pathways involving transduction of the effects of Dex
on musculoskeletal cells have been widely discussed in the liter-
ature42e45. Our ongoing studies utilize a phosphoproteomics
approach focused on pathways by which Dex may regulate chon-
drocyte apoptosis, though this is beyond the scope of the present
study.
In vivo, both chondroprotective and deleterious effects have
both been reported upon intra-articular injection of GCs. Intra-
articular injection of GCs typically involves very high doses (e.g.,
up to ~100 mM44,46, compared to the 100 nM Dex concentrations
used in the present study). Such high-dose intra-articular in-
jections47,48 have caused systemic side effects. Thus, therapeutic
efﬁcacy would be greatly aided by methods to deliver low con-
centrations of Dex directly inside cartilage so as to appropriately
minimize exposure of Dex to other joint tissues such as tendon,
ligament and meniscus28.
In contrast to our ﬁndings with young bovine cartilage, both the
anti-catabolic and pro-cell-survival effects of IGF-1 were lost with
adult human ankle and knee cartilage. Substantial evidence in the
literature has shown that OA and aging chondrocytes respond
poorly to IGF-149,50, due to the presence of IGF-1 binding proteins
(IGF-BPs) in the matrix51,52 and to altered intracellular signaling by
mediators such as reactive oxygen species53. Yin et al.17 demon-
strated that oxidative stress is responsible for inhibiting Akt
phosphorylation and stimulating MEK-ERK MAPK signaling in hu-
man OA chondrocytes and, as a result, IGF-1 signaling was blocked
along with proteoglycan synthesis. In the present study, we found
that IGF-1 could signiﬁcantly rescue IL-1a-suppressed proteoglycan
biosynthesis in human cartilage but did not affect proteoglycan
degradation. Ongoing studies of these differences in the response
between human and bovine cartilage to such combination thera-
peutics provide a unique opportunity to determine the mecha-
nisms which account for cell sensitivity to IGF-1 or Dex treatment.
An understanding of these mechanisms will aid in translating these
in vitro data to clinical applications.
In summary, we demonstrated the beneﬁcial effects of the
combination of IGF-1 and Dex in reversing IL-1a-suppressed
biosynthesis and blocking cytokine-induced proteoglycan and
collagen degradation in young bovine explants. Furthermore, IGF-
Y. Li et al. / Osteoarthritis and Cartilage 23 (2015) 266e274 2731 þ Dex strongly inhibited cell death induced in an inﬂammatory
environment. Importantly, we showed that each therapeutic factor
has a unique role in cytokine-challenged adult human cartilage:
IGF-1 stimulated proteoglycan biosynthesis while Dex ameliorated
cartilage catabolism. Consequently, the result from this study
highlights the need to investigate combination therapeutics in
clinical settings. The advantageous effects of this combination
therapy could be further enhanced by using a cartilage matrix
binding variant of IGF-154 as well as appropriate in vivo delivery
methods, e.g., intra-articular injection with cartilage-homing
nanoparticles that may be relevant for treatment of early stage
PTOA28.
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